SYNTHETIC CANNABINOIDS

There were 117 synthetic cannabinoid identifications in the first quarter of CY 2017. FUB-AMB accounted for approximately 43% of the identifications. There was a significant increase in the number of synthetic cannabinoid identifications, increasing from 31 identifications during the fourth quarter of CY 2016 to 117 identifications in the first quarter of CY 2017 (a 377% increase).

Tryptamines

No substituted tryptamines were identified during the reporting period.

OPIOIDS/ANALGESICS

There were 230 identifications of fentanyl, fentanyl-related substances, and other synthetic opioids. Fentanyl accounted for approximately 58% of the identifications. The next most prominent fentanyl-related substance, furanyl fentanyl, accounted for 26% of the identifications. Of the 134 fentanyl identifications, fentanyl was found as the only controlled substance in approx. 28% of the identifications and was found in combination with heroin in approx. 61% of the identifications.

CATHINONES

There were 40 cathinone identifications in the first quarter of CY 2017. N-ethylpentylone accounted for approximately 55% of the identifications. Other controlled substances identified with fentanyl this quarter include U-47700, alprazolam, heroin, ketamine, and cocaine.

Hallucinogens

There was 1 identification of 25I-NBOMe during the reporting period.

Other

There were 2 instances of unconfirmed substances this quarter. There were 7 identifications of etizolam, 2 identifications of dimethylamylamine (DMAA), and 1 identification each of 4-methoxyphenylpiperazine and 5-EAPB.